Been waiting for this week for a loooonnnggg time.

The addition of Donald is fantastic. One more jewel in the crown.

I am going to assume that LymPro data is good/excellent for the sake of this post.

My best guess is .25 by Friday.

Revenue guidance = another .05 - .10 cents.

LymPro partnership adds .10 -.20 cents dependent on up front payments. If it is both a CLIA partner and Pharma partner for FDA approval, could be more.

This would put pps at .40 - .55 cents by end of August.

You throw in some additional MANF catalysts/partnerships and we're looking at .75 - 1.00 by up listing.

I'm finally allowing my imagination to run free.

Great times ahead.